Key statistics
On Monday, Jazz Pharmaceuticals PLC (J7Z:DEU) closed at 98.52, 7.30% above its 52-week low of 91.82, set on Jul 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 99.02 |
---|---|
High | 100.20 |
Low | 97.56 |
Bid | 98.70 |
Offer | 99.10 |
Previous close | 99.28 |
Average volume | 33.30 |
---|---|
Shares outstanding | 61.75m |
Free float | 59.97m |
P/E (TTM) | 18.79 |
Market cap | 6.75bn USD |
EPS (TTM) | 5.82 USD |
Data delayed at least 15 minutes, as of Oct 07 2024.
More ▼
Press releases
- Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
- Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024
- Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024
- Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases
- Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases
- Jazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies
- Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
- Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting
- Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026
- Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024
More ▼